Volver
Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/87725
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSantoro, Francesco-
dc.contributor.authorNuñez-Gil, Ivan Javier-
dc.contributor.authorVitale, Enrica-
dc.contributor.authorViana-Llamas, Maria C-
dc.contributor.authorReche-Martinez, Begoña-
dc.contributor.authorRomero-Pareja, Rodolfo-
dc.contributor.authorFeltez Guzman, Gisela-
dc.contributor.authorFernandez Rozas, Inmaculada-
dc.contributor.authorUribarri, Aitor-
dc.contributor.authorBecerra-Muñoz, Víctor Manuel-
dc.contributor.authorAlfonso-Rodriguez, Emilio-
dc.contributor.authorGarcia-Aguado, Marcos-
dc.contributor.authorHuang, Jia-
dc.contributor.authorOrtega-Armas, María Elizabeth-
dc.contributor.authorGarcia Prieto, Juan F-
dc.contributor.authorCorral Rubio, Eva Maria-
dc.contributor.authorUgo, Fabrizio-
dc.contributor.authorBianco, Matteo-
dc.contributor.authorMulet, Alba-
dc.contributor.authorRaposeiras-Roubin, Sergio-
dc.contributor.authorJativa Mendez, Jorge Luis-
dc.contributor.authorEspejo Paeres, Carolina-
dc.contributor.authorAlbarrán, Adrián Rodríguez-
dc.contributor.authorMarín, Francisco-
dc.contributor.authorGuerra, Federico-
dc.contributor.authorAkin, Ibrahim-
dc.contributor.authorCortese, Bernardo-
dc.contributor.authorRamakrishna, Harish-
dc.contributor.authorMacaya, Carlos-
dc.contributor.authorFernandez-Ortiz, Antonio-
dc.contributor.authorBrunetti, Natale Daniele-
dc.date.accessioned2023-09-15T08:37:59Z-
dc.date.available2023-09-15T08:37:59Z-
dc.date.issued2022-01-
dc.identifier.citationHeart.2022 Jan;(108)2:130-136es_ES
dc.identifier.issn1355-6037-
dc.identifier.urihttps://hdl.handle.net/20.500.12530/87725-
dc.description.abstractStandard therapy for COVID-19 is continuously evolving. Autopsy studies showed high prevalence of platelet-fibrin-rich microthrombi in several organs. The aim of the study was therefore to evaluate the safety and efficacy of antiplatelet therapy (APT) in hospitalised patients with COVID-19 and its impact on survival.es_ES
dc.language.isoenes_ES
dc.publisherBMJes_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectCOVID-19es_ES
dc.subjectclinicales_ES
dc.subjectpharmacologyes_ES
dc.subject.meshAgedes_ES
dc.subject.meshCOVID-19es_ES
dc.subject.meshFemalees_ES
dc.subject.meshHospital Mortalityes_ES
dc.subject.meshHospitalizationes_ES
dc.subject.meshHumanses_ES
dc.subject.meshMalees_ES
dc.subject.meshMiddle Agedes_ES
dc.subject.meshPlatelet Aggregation Inhibitorses_ES
dc.subject.meshRegistrieses_ES
dc.subject.meshRespiration, Artificiales_ES
dc.subject.meshCOVID-19 Drug Treatmentes_ES
dc.titleAntiplatelet therapy and outcome in COVID-19: the Health Outcome Predictive Evaluation Registryes_ES
dc.typeArtículoes_ES
dc.identifier.pubmedID34611045es_ES
dc.format.volume108es_ES
dc.format.page130es_ES
dc.description.peerreviewedSíes_ES
dc.identifier.journalHeart (British Cardiac Society)es_ES
dc.contributor.authoraffiliationHospital Universitario Príncipe de Asturiases_ES
dc.format.number2es_ES
Appears in Collections:Hospitales > H. U. Príncipe de Asturias > Artículos

Files in This Item:
File Description SizeFormat 
34611045.pdfAntiplatelet therapy and outcome in COVID-19701.49 kBAdobe PDFView/Open
Show simple item record

Google Scholar ???export.bibtex.alt???


This item is licensed under a Creative Commons License Creative Commons